(firstQuint)Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer.

 Initially, the safety, side effects and recommended phase 2 dose of oral Karenitecin in patients with advanced solid tumors will be determined.

 When the recommended phase 2 dose has been determined, the specified dose will be used to determine if Karenitecin is effective in the treatment of patients with relapsed or refractory non-small cell lung cancer.

.

 Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer@highlight

The purpose of this study is to determine the maximum safe dose of orally administered Karenitecin (BNP1350) in patients with solid tumors.

